The purported mechanism is through IL2-mediated sensitization of the tumor microenvironment to increase PD-L1 expression and increase CD8+ T cell infiltration, thus increasing the anti-PD-1 treatment efficacy. The gene discussed is IL2; the disease is neoplasm.